215 related articles for article (PubMed ID: 16550259)
21. Gastrointestinal stromal tumors: review on morphology, molecular pathology, diagnostics, prognosis and treatment options.
Paral J; Slaninka I; Kalabova H; Hadzi-Nikolov D
Acta Gastroenterol Belg; 2010; 73(3):349-59. PubMed ID: 21086937
[TBL] [Abstract][Full Text] [Related]
22. Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients.
Saied GM; Kensarah AM
Int J Surg; 2010; 8(2):105-8. PubMed ID: 19944196
[TBL] [Abstract][Full Text] [Related]
23. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
24. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
[TBL] [Abstract][Full Text] [Related]
25. [Current aspects of treatment in gastrointestinal stromal tumors (GIST)].
Láng I; Hitre E
Orv Hetil; 2005 May; 146(18 Suppl 1):935-41. PubMed ID: 15921308
[TBL] [Abstract][Full Text] [Related]
26. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
27. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
Keung EZ; Fairweather M; Raut CP
Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
[TBL] [Abstract][Full Text] [Related]
28. Neoodjuvant imatinib mesylate for advanced primary and metastactic/recurrent gastro-intestinal stromal tumour (GIST).
Das D; Ganguly S; Deb AR; Aich RK
J Indian Med Assoc; 2013 Jan; 111(1):21-3. PubMed ID: 24000503
[TBL] [Abstract][Full Text] [Related]
29. Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG).
Duffaud F; Meeus P; Bertucci F; Delhorme JB; Stoeckle E; Isambert N; Bompas E; Gagniere J; Bouché O; Toulmonde M; Salas S; Blay JY; Bonvalot S;
Eur J Surg Oncol; 2017 Jun; 43(6):1110-1116. PubMed ID: 28433494
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal stromal tumors: risk assessment and adjuvant therapy.
Joensuu H
Hematol Oncol Clin North Am; 2013 Oct; 27(5):889-904. PubMed ID: 24093166
[TBL] [Abstract][Full Text] [Related]
31. Current management of gastrointestinal stromal tumors--a comprehensive review.
Lai EC; Lau SH; Lau WY
Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
[TBL] [Abstract][Full Text] [Related]
32. New fronts in the adjuvant treatment of GIST.
Reichardt P; Joensuu H; Blay JY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
[TBL] [Abstract][Full Text] [Related]
33. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
34. [Gastrointestinal stromal tumor (GIST)--medical rarities?].
Predescu D; Gheorghe M; Predoiu I; Iosif C; Constantin A; Chiru F; Cociu L; Constantinoiu S
Chirurgia (Bucur); 2010; 105(4):577-85. PubMed ID: 20941986
[TBL] [Abstract][Full Text] [Related]
35. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
[TBL] [Abstract][Full Text] [Related]
36. [Gastrointestinal stromal tumors].
Zabka J
Klin Onkol; 2011; 24(3):187-94. PubMed ID: 21717788
[TBL] [Abstract][Full Text] [Related]
37. Imaging surveillance of gastrointestinal stromal tumour: current recommendation by National Comprehensive Cancer Network and European Society of Medical Oncology-European Reference Network for rare adult solid cancers.
Alessandrino F; Tirumani SH; Jagannathan JP; Ramaiya NH
Clin Radiol; 2019 Oct; 74(10):746-755. PubMed ID: 31345555
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
39. Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes.
Marano L; Boccardi V; Marrelli D; Roviello F
Eur J Surg Oncol; 2015 Jul; 41(7):814-22. PubMed ID: 25956211
[TBL] [Abstract][Full Text] [Related]
40. Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor.
Hsu KH; Yang TM; Shan YS; Lin PW
Am J Surg; 2007 Aug; 194(2):148-52. PubMed ID: 17618793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
